Edward Kim
Medical Oncology · Charlotte, NCNPI 1972688984
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 22.3%. Reporting peaked in 2019 at $68,177 and has fallen 72.9% since, to $18,479 in 2025. Among medical oncology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 192 payments — averaging $977.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$42K
- AstraZeneca$28K
- Boehringer Ingelheim$20K
- Genentech USA, Inc.$14K
- Boehringer Ingelheim International GmbH$13K
- Astrazeneca UK Limited$8K
- plus $62K from 28 others
Across 83 payments — averaging $18,007 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$814K
- Astrazeneca UK Limited$183K
- AstraZeneca$180K
- Genentech, Inc.$173K
- Incyte Corporation$41K
- Regeneron$34K
- plus $70K from 7 others
What the payments were for
- Consulting fees$105,95956%
- Speaking & faculty fees$55,41030%
- Grants$1830%
- Travel & lodging$19,16110%
- Food & beverage$5,0403%
- Education$1,7421%
- Charitable contribution$1800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 26 | $41,850 |
| AstraZeneca | 20 | $28,441 |
| Boehringer Ingelheim | 13 | $20,347 |
| Genentech USA, Inc. | 9 | $13,838 |
| Boehringer Ingelheim International GmbH | 8 | $12,819 |
| Astrazeneca UK Limited | 8 | $8,238 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 8 | $7,642 |
| Roche Molecular Systems, Inc. | 14 | $6,570 |
| F. Hoffmann-la Roche AG | 5 | $5,249 |
| Partner Therapeutics, Inc. | 9 | $5,002 |
| EMD Serono, Inc. | 1 | $4,550 |
| Eli Lilly | 1 | $4,200 |
| GSK | 3 | $4,065 |
| Pfizer | 4 | $3,841 |
| E.r. Squibb & Sons, L.L.C. | 5 | $3,600 |
| Sanofi | 5 | $2,928 |
| Gilead | 2 | $2,528 |
| Lilly USA, LLC | 7 | $2,128 |
| Merck | 6 | $1,542 |
| Roche Sequencing Solutions, Inc. | 1 | $1,500 |
| Array Biopharma Inc | 2 | $1,491 |
| Regeneron | 1 | $1,310 |
| Bayer | 4 | $1,242 |
| Exelixis Inc. | 1 | $660 |
| Celltrion, Inc. | 1 | $600 |
| Mirati Therapeutics, Inc. | 3 | $596 |
| Intuitive Surgical | 3 | $256 |
| Boston Scientific | 15 | $206 |
| Johnson & Johnson | 2 | $114 |
| Daiichi Sankyo Inc. | 1 | $108 |
| Amgen | 1 | $80 |
| Novocure Inc. | 1 | $47 |
| AbbVie | 1 | $47 |
| Masimo Corporation | 1 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$187,675 in reported general payments places this provider in the 90th percentile of 170 medical oncology providers in North Carolina.
Other medical oncology in Charlotte
- David RizzieriCharlotte$714K
- Nilanjan GhoshCharlotte$510K
- Mohamed SalemCharlotte$396K
- Kathryn MilehamCharlotte$110K
- Antoinette TanCharlotte$89K
- Jimmy HwangCharlotte$64K
- Ashley SumrallCharlotte$55K
- Obiageli OgbataCharlotte$26K
- Daniel CarrizosaCharlotte$20K
- Daniel HaggstromCharlotte$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.